RxDoctor Payments DataLook up a doctor →

Malwinder Singha, MD

Vascular & Interventional Radiology · Rancho Cucamonga, CANPI 1972558203

Payments from drug & device makers

$251,580in general payments, 2019–2025

Across 368 payments — averaging $683.64 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$198K
  • Cardiovascular Systems Inc.$21K
  • Cook Incorporated$16K
  • Cook Medical LLC$3K
  • Nevro Corp.$3K
  • Nalu Medical, Inc.$1K
  • plus $9K from 25 others

What the payments were for

  • Consulting fees$3000%
  • Speaking & faculty fees$33,64013%
  • Travel & lodging$4,1672%
  • Food & beverage$15,6426%
  • Education$1,0810%
  • Other$196,75078%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$251,580 in reported general payments places this provider in the 90th percentile of 504 vascular & interventional radiology providers in California.

See all vascular & interventional radiology providers in California

Medicare billing

Part B allowed, 2024
$7,753,105
Medicare patients
287
Services billed
28,833

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban100$71,639
XareltoRivaroxaban80$52,094
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam59$9,113
Vancomycin Hcl58$6,297
ClopidogrelClopidogrel Bisulfate384$4,000
Meropenem17$1,416
Pregabalin47$952
Gabapentin19$495
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen23$376
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim55$362
Famotidine32$231
Tramadol Hcl76$207
Sodium Chloride0.9 % Sodium Chloride20$179
Cephalexin11$85
Ibuprofen14$55

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$137$71,639100 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 504 vascular & interventional radiology providers in California.

Other vascular & interventional radiology in Rancho Cucamonga

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →